sometexan84
Senior Member
- Messages
- 1,241
First off, it must be noted that Frank Comhaire holds the patent for the use of sodium dichloroacetate for the treatment of ME/CFS. So, a bit of a conflict of interest...
And he did the 2018 (not 2016, I'd put the wrong year) study Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial.
As well as the other two I'm going to mention.
In his late 2018 follow-up, (Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?) he mentions possible co-morbidities and auto-immunity as potential reasons for non-responders.
In 2019, his update News and views in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): The role of co-morbidity and novel treatments, he talks about potential treatment w/ the following combo, which I found interesting....
I've been looking into this a bit lately.
Dietrich Klinghardt did a Feb 2020 conference in London, "A Future without ME/CFS", in his slides he mentions Meldonium combined w/ DCA (sodium dichloroacetate).
He says "I combine DCA (20 mg/kg) with Meldonium for rapid and excellent improvement of many ME symptoms"
...and that Meldonium "is a game changer in ME"
That said, @ljimbo423 is correct, it doesn't address the whole problem. The above solutions do not seem to address EBV infected cells, or cells affected by HHV-6, both of which seem to cause a different kind of mito dysfunction. Nor does it address other infections, or auto-immune issues, or the deregulated immune system by EBV (epigenetic miRNA deregulation and DNA methylation dysregulation).
And he did the 2018 (not 2016, I'd put the wrong year) study Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial.
As well as the other two I'm going to mention.
In his late 2018 follow-up, (Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?) he mentions possible co-morbidities and auto-immunity as potential reasons for non-responders.
In 2019, his update News and views in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): The role of co-morbidity and novel treatments, he talks about potential treatment w/ the following combo, which I found interesting....
"Metformin, or possibly Momordica charantia extract, which will correct insulin resistance, with Meldonium improving the transportation of glucose into the mitochondria, with sodium dichloroacetate activating pyruvate dehydrogenase, and with nutraceutical support reducing oxidative and inflammatory impairment"
I've been looking into this a bit lately.
Dietrich Klinghardt did a Feb 2020 conference in London, "A Future without ME/CFS", in his slides he mentions Meldonium combined w/ DCA (sodium dichloroacetate).
He says "I combine DCA (20 mg/kg) with Meldonium for rapid and excellent improvement of many ME symptoms"
...and that Meldonium "is a game changer in ME"
That said, @ljimbo423 is correct, it doesn't address the whole problem. The above solutions do not seem to address EBV infected cells, or cells affected by HHV-6, both of which seem to cause a different kind of mito dysfunction. Nor does it address other infections, or auto-immune issues, or the deregulated immune system by EBV (epigenetic miRNA deregulation and DNA methylation dysregulation).